Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read General business news Is Expleo Solutions (NSE: EXPLEOSOL) entering a margin reset phase after Q2FY26 earnings surprise? Expleo Solutions posts Q2FY26 earnings surprise with margin rebound and 74% profit surge. See how AI, digital deals, and regional mix are reshaping the outlook. byVenkateshNovember 14, 2025